XML 15 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONSOLIDATED STATEMENTS OF (LOSS) INCOME - USD ($)
shares in Millions, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Revenues        
Product sales $ 2,388.7 $ 2,695.0 $ 4,724.8 $ 4,821.1
Other revenues 31.5 37.4 67.0 81.4
Total revenues 2,420.2 2,732.4 4,791.8 4,902.5
Operating Expenses        
Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below) 647.3 669.9 1,267.5 1,177.8
Cost of other revenues 10.5 15.2 20.2 29.5
Selling, general and administrative 671.5 685.5 1,484.1 1,259.3
Research and development 124.3 81.1 227.4 136.9
Amortization and impairments of finite-lived intangible assets 887.6 585.4 1,582.1 950.6
Restructuring, integration and other costs 19.5 143.4 57.5 198.4
In-process research and development impairments and other charges 17.4 12.3 17.9 12.3
Acquisition-related costs 0.0 9.5 1.8 23.4
Acquisition-related contingent consideration 6.9 11.7 9.3 18.8
Other (income) expense (45.3) 176.9 (22.7) 183.0
Total expenses 2,339.7 2,390.9 4,645.1 3,990.0
Operating income 80.5 341.5 146.7 912.5
Interest income 2.1 0.9 3.0 1.8
Interest expense (472.5) (412.7) (899.1) (710.5)
Loss on extinguishment of debt 0.0 0.0 0.0 (20.0)
Foreign exchange and other 13.1 5.6 6.9 (65.5)
(Loss) income before (recovery of) provision for income taxes (376.8) (64.7) (742.5) 118.3
(Recovery of) provision for income taxes (72.8) (13.1) (65.6) 71.4
Net (loss) income (304.0) (51.6) (676.9) 46.9
Less: Net (loss) income attributable to noncontrolling interest (1.7) 1.4 (0.9) 2.2
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc. $ (302.3) $ (53.0) $ (676.0) $ 44.7
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.:        
Basic (in usd per share) $ (0.88) $ (0.15) $ (1.96) $ 0.13
Diluted (in usd per share) $ (0.88) $ (0.15) $ (1.96) $ 0.13
Weighted-average common shares outstanding (in millions)        
Basic (in shares) 345.0 344.4 344.9 340.5
Diluted (in shares) 345.0 344.4 344.9 347.1